Cas no 382-52-5 (9α-Fluoro-6α-methylprednisolone)
9α-Fluoro-6α-methylprednisolone Chemical and Physical Properties
Names and Identifiers
-
- (6alpha,11beta)-9-fluoro-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- 6.α.-Methyl-9.α.-fluoroprednisolone
- 9α-Fluoro-6α-methylprednisolone
- 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-
- Q27148958
- NSC-19621
- UNII-J2I9Y46AHB
- 6.alpha.-Methyl-9.alpha.-fluoroprednisolone
- PREGNA-1,4-DIENE-3,20-DIONE,9-FLUORO-11.BETA.,17,21-TRIHYDROXY-6.ALPHA.-METHYL-
- 9.ALPHA.-FLUORO-11.BETA.,17.ALPHA.,21-TRIHYDROXY-6.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-
- CHEMBL3250062
- Pregna-1,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-6.alpha.-methyl-
- (6S,8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
- SCHEMBL3396894
- Pregna-1,4-diene-3,20-dione,9-fluoro-11beta,17,21-trihydroxy-6alpha-methyl-
- CHEBI:79821
- Pregna-1,20-dione, 9-fluoro-11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-
- 9alpha-Fluoro-6alpha-methylprednisolone; (6?,11?)-9-Fluoro-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11?,17,21-trihydroxy-6?-methyl- (7CI,8CI); 6?-Methyl-9?-fluoroprednisolone; 9?-Fluoro-11?,17?,21-trihydroxy-6?-methylpregna-1,4-diene-3,20-dio
- NSC-48986
- J2I9Y46AHB
- (6a, 11)-9-fluoro-11,17, 21-Trihydroxy-6-Methylpregna-1, 4-Diene-3, 20-Dione
- NSC48986
- 382-52-5
- 9alpha-Fluoro-6alpha-methylprednisolone
- 6alpha-methyl-9alpha-fluoroprednisolone
- NSC19621
- 9.alpha.-Fluoro-6.alpha.-methylprednisolone
-
- Inchi： 1S/C22H29FO5/c1-12-8-16-14-5-7-21(28,18(27)11-24)20(14,3)10-17(26)22(16,23)19(2)6-4-13(25)9-15(12)19/h4,6,9,12,14,16-17,24,26,28H,5,7-8,10-11H2,1-3H3/t12-,14-,16-,17-,19-,20-,21-,22-/m0/s1
- InChI Key： AWFOJLJWZNBTBX-MJWISQFFSA-N
- SMILES： F[C@@]12[C@]3(C=CC(C=C3[C@@H](C)C[C@H]1[C@@H]1CC[C@](C(CO)=O)([C@@]1(C)C[C@@H]2O)O)=O)C
Computed Properties
- Exact Mass: 392.19997
- Monoisotopic Mass: 392.2
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 28
- Rotatable Bond Count: 2
- Complexity: 805
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 8
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 1.9
- Topological Polar Surface Area: 94.8A^2
Experimental Properties
- Density: 1.32
- Boiling Point: 568.2°C at 760 mmHg
- Flash Point: 297.5°C
- Refractive Index: 1.591
- PSA: 94.83
- LogP: 1.89570
9α-Fluoro-6α-methylprednisolone Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | F596115-50mg |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 50mg |
$ 110.00 | 2023-04-17 | ||
| TRC | F596115-100mg |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 100mg |
$ 167.00 | 2023-04-17 | ||
| TRC | F596115-500mg |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 500mg |
$ 345.00 | 2023-04-17 | ||
| TRC | F596115-1g |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 1g |
$ 570.00 | 2022-06-04 | ||
| TRC | F596115-2.5g |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 2.5g |
$ 4500.00 | 2023-09-07 | ||
| TRC | F596115-5g |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 5g |
$ 2738.00 | 2023-04-17 | ||
| TRC | F596115-1000mg |
9α-Fluoro-6α-methylprednisolone |
382-52-5 | 1g |
$ 689.00 | 2023-04-17 |
9α-Fluoro-6α-methylprednisolone Related Literature
-
Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
-
Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
-
Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
-
Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
-
Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
Additional information on 9α-Fluoro-6α-methylprednisolone
Comprehensive Overview of 9α-Fluoro-6α-methylprednisolone (CAS No. 382-52-5): Properties, Applications, and Research Insights
9α-Fluoro-6α-methylprednisolone (CAS No. 382-52-5) is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. This compound, a fluorinated derivative of methylprednisolone, has garnered significant attention in pharmaceutical research due to its enhanced biological activity and therapeutic potential. The addition of a 9α-fluoro group and 6α-methyl moiety significantly alters its pharmacokinetic profile, making it a subject of interest for drug development and clinical applications.
In recent years, the demand for specialized glucocorticoids like 9α-Fluoro-6α-methylprednisolone has surged, driven by advancements in autoimmune disease treatments and inflammation management. Researchers and clinicians frequently search for terms such as "glucocorticoid potency comparison", "fluorinated steroids benefits", and "methylprednisolone derivatives" to explore its unique mechanisms. The compound's ability to modulate gene expression and inhibit pro-inflammatory cytokines positions it as a candidate for conditions like rheumatoid arthritis, asthma, and dermatological disorders.
The molecular structure of CAS No. 382-52-5 features critical modifications that enhance its receptor binding affinity. The 9α-fluoro substitution increases glucocorticoid receptor (GR) activation, while the 6α-methyl group reduces mineralocorticoid activity, minimizing side effects like fluid retention. These attributes align with current trends in precision medicine, where targeted therapies with fewer adverse effects are prioritized. Searches for "steroid structure-activity relationship" and "GR agonist selectivity" reflect growing interest in this niche.
From a formulation perspective, 9α-Fluoro-6α-methylprednisolone presents challenges and opportunities in drug delivery. Its low solubility in aqueous media has spurred investigations into nanocarriers and liposomal encapsulation—topics frequently queried as "improving steroid bioavailability". Recent studies also explore its synergy with biologics, addressing search trends like "combination therapy for inflammation". Such innovations aim to overcome limitations while maximizing therapeutic outcomes.
Ongoing research into 382-52-5 extends beyond traditional applications. Exploratory studies examine its role in neuroprotection and oncology, responding to queries such as "glucocorticoids in cancer immunotherapy". However, its use requires careful dose optimization due to potential HPA axis suppression—a concern highlighted in searches for "steroid taper protocols". Regulatory agencies emphasize rigorous safety profiling, ensuring compliance with evolving guidelines on synthetic glucocorticoids.
In conclusion, 9α-Fluoro-6α-methylprednisolone exemplifies the intersection of medicinal chemistry and therapeutic innovation. Its optimized pharmacokinetics and expanding applications address pressing healthcare needs while inspiring future research. As the scientific community continues to investigate queries like "next-gen anti-inflammatory agents", this compound remains a pivotal reference in glucocorticoid pharmacology.
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
